You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News and reporting on lung cancer.
The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.
The Spanish firm also expects to release clinical data on its early-stage, next-generation sequencing-based colorectal cancer test in the first half of 2021.
The firm will use the funds to accelerate clinical development and continued rollout of its RaDaR minimal residual disease (MRD) detection and recurrence assay.
The company's two largest investors will purchase $25 million of its common shares, with proceeds supporting ongoing test commercialization.
Natera alleges Inivata infringes its US Patent Nos. 10,262,755 and 10,597,709, which cover cancer monitoring and molecular residual disease testing.
The companies said Tuesday that they are pursuing a clinical trial utilizing their respective liquid biopsy assays on clinical samples from lung cancer patients.
AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib.
The Universities of Southampton and Leeds will lead the project with participation from Johnson & Johnson, Roche, Oncimmune, BC Platforms, Inivata, and NHS England.
The rating increase follows Oncocyte's Chinese distribution deal for its DetermaRx lung cancer treatment stratification test with Burning Rock Biotech.
The firm said that the National Institute for Health and Care Excellence has selected its EarlyCDT Lung test for its Diagnostics Assessment Guidance.